Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
Launched by NATIONAL TAIWAN UNIVERSITY HOSPITAL · Nov 5, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how certain blood components can help predict the outcomes for patients with recurrent or metastatic head and neck cancers, specifically squamous cell carcinoma. The researchers want to investigate the relationship between circulating tumor cells (CTC) and circulating tumor emboli (CTM) in the blood, along with the role of natural killer (NK) cells, which are important immune cells. By analyzing blood samples from patients, the study aims to see how these factors relate to treatment success and overall patient prognosis.
To participate in this trial, individuals must be at least 20 years old and have a confirmed diagnosis of recurrent or metastatic squamous cell carcinoma in specific areas of the head and neck that cannot be treated with local therapies. They should also have measurable tumor lesions and be in relatively good health according to a standard performance scale. Participants will provide blood samples for analysis while undergoing treatment from their primary doctors. It's important to note that the trial is not yet recruiting participants, so interested individuals should stay updated for when it begins.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: must fulfill with all the items below
- • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2.
- • \>=20 years old.
- • had pathologically confirmed squamous cell carcinoma of the oropharynx, oral cavity, hypopharynx, or larynx that was recurrent or metastatic and not curable by local therapy.
- • had at least one tumor lesion measurable per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- • Medical records during treatment are available.
- Exclusion Criteria:
- • Medical records during treatment unavailable
- • Could not cooperate with blood sampling
- • Without informed consent
About National Taiwan University Hospital
National Taiwan University Hospital (NTUH) is a leading medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. As a pioneer in medical education and patient care in Taiwan, NTUH integrates cutting-edge technology with comprehensive clinical expertise to facilitate groundbreaking studies across various medical fields. The hospital’s dedicated research team collaborates with local and international partners to enhance the understanding of diseases and improve treatment outcomes. By prioritizing patient safety and ethical standards, NTUH strives to contribute to the global medical community and foster advancements in healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhubei City, , Taiwan
Zhubei City, Hsinchu County, Taiwan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported